|
Daehan Nupharm Achieves Annual Sales of KRW 204.2 Billion in 2023
2024.03.13
|
|---|
|
Daehan Nupharm recorded KRW 204.2 billion in annual sales for 2023, achieving its highest sales performance to date, along with KRW 18.8 billion in operating profit and KRW 12.5 billion in net profit. The company continues to focus on product research and development across its key business divisions—pharmaceuticals, veterinary medicine, biotechnology, and health functional foods. In addition to the recently launched Rapiduo Tab., R&D efforts are actively underway for improved combination drugs for hypertension, hyperlipidemia, and obesity treatment.
Currently, most antifungal agents prescribed in domestic animal hospitals are human medications. Although fungal skin diseases, including Malassezia infections, are common in companion animals, there has been a lack of approved veterinary drugs, highlighting the need for safe and effective animal-specific antifungal treatments. Daehan Nupharm plans to continuously introduce new products that meet veterinarians’ clinical needs.
Through ongoing research and development, the company has successfully developed DH Fuzole Tab. as a veterinary medicine based on its existing human formulation. By pursuing R&D strategies that create synergy across business divisions, Daehan Nupharm aims to launch innovative products and maintain sustainable growth. |


Home